SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

SAN

82.99

-1.43%↓

MRK1

112.5

-1.53%↓

SHL.DE

46.33

-3.42%↓

ARGX

477.1

-1.28%↓

FRE

41.87

-0.69%↓

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

4.45 -4.4

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.34

Max

4.45

Põhinäitajad
By Trading Economics
Sissetulek	-46M
Müük	-21M
Kasumimarginaal	221.361
Töötajad	108
EBITDA	-38M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+122.63% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	15. juuli 2025

Turustatistika
By TradingEconomics
Turukapital	197M
Eelmine avamishind	8.85
Eelmine sulgemishind	4.45

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. juuli 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

FCC Approves U.S. Cellular Sale to T-Mobile

11. juuli 2025, 17:28 UTC

Suurimad hinnamuutused turgudel

SharpLink Gaming Gains on Ethereum Purchase

11. juuli 2025, 16:57 UTC

Tulu

BASF Cuts Outlook on Global Economy Uncertainty

11. juuli 2025, 21:45 UTC

Market Talk

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11. juuli 2025, 19:46 UTC

Omandamised, ülevõtmised, äriostud

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11. juuli 2025, 19:45 UTC

Market Talk

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11. juuli 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11. juuli 2025, 18:18 UTC

Market Talk

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11. juuli 2025, 17:35 UTC

Market Talk

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11. juuli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11. juuli 2025, 16:53 UTC

Market Talk

Crude Futures Add to Early Gains -- Market Talk

11. juuli 2025, 16:42 UTC

Tulu

BASF Cuts Outlook on Global Economic Uncertainty

11. juuli 2025, 16:08 UTC

Market Talk

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11. juuli 2025, 16:05 UTC

Tulu

BASF Will Publish Half-Year Results on July 30

11. juuli 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

11. juuli 2025, 16:04 UTC

Market Talk

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11. juuli 2025, 16:03 UTC

Tulu

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11. juuli 2025, 16:02 UTC

Tulu

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11. juuli 2025, 16:01 UTC

Tulu

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11. juuli 2025, 16:00 UTC

Tulu

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11. juuli 2025, 15:59 UTC

Tulu

BASF Cuts 2025 Earnings View

11. juuli 2025, 15:58 UTC

Tulu

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11. juuli 2025, 15:57 UTC

Tulu

BASF 2Q EBIT Before Special Items EUR810M

11. juuli 2025, 15:54 UTC

Tulu

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11. juuli 2025, 15:54 UTC

Tulu

BASF 2Q Sales Fell 2.1% on Year

11. juuli 2025, 15:53 UTC

Tulu

BASF 2Q Sales EUR15.77B

11. juuli 2025, 15:52 UTC

Tulu

BASF: This Was in Line With Consensus Estimates

11. juuli 2025, 15:52 UTC

Tulu

BASF 2Q Ebitda Before Special Items EUR1.77B

11. juuli 2025, 15:49 UTC

Tulu

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11. juuli 2025, 15:41 UTC

Market Talk

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

122.63% tõus

12 kuu keskmine prognoos

Keskmine 10.33 EUR 122.63%

Kõrge 17 EUR

Madal 4 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.